[go: up one dir, main page]

FI20011664L - Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö - Google Patents

Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö Download PDF

Info

Publication number
FI20011664L
FI20011664L FI20011664A FI20011664A FI20011664L FI 20011664 L FI20011664 L FI 20011664L FI 20011664 A FI20011664 A FI 20011664A FI 20011664 A FI20011664 A FI 20011664A FI 20011664 L FI20011664 L FI 20011664L
Authority
FI
Finland
Prior art keywords
cancer
oligosaccharide sequences
specific oligosaccharide
specific
sequences
Prior art date
Application number
FI20011664A
Other languages
English (en)
Swedish (sv)
Other versions
FI20011664A0 (fi
FI20011664A7 (fi
Inventor
Juhani Saarinen
Jari Helin
Original Assignee
Carbion Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carbion Oy filed Critical Carbion Oy
Priority to FI20011664A priority Critical patent/FI20011664A7/fi
Publication of FI20011664A0 publication Critical patent/FI20011664A0/fi
Priority to EP02748913A priority patent/EP1417214A2/en
Priority to JP2003521773A priority patent/JP2005500057A/ja
Priority to US10/486,714 priority patent/US8313912B2/en
Priority to PCT/FI2002/000674 priority patent/WO2003016464A2/en
Priority to AU2002319338A priority patent/AU2002319338A1/en
Publication of FI20011664L publication Critical patent/FI20011664L/fi
Publication of FI20011664A7 publication Critical patent/FI20011664A7/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI20011664A 2001-08-17 2001-08-17 Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö FI20011664A7 (fi)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20011664A FI20011664A7 (fi) 2001-08-17 2001-08-17 Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
EP02748913A EP1417214A2 (en) 2001-08-17 2002-08-16 Cancer specific oligosaccharide sequences and use thereof
JP2003521773A JP2005500057A (ja) 2001-08-17 2002-08-16 癌特異的オリゴ糖配列およびその用途
US10/486,714 US8313912B2 (en) 2001-08-17 2002-08-16 Cancer specific oligosaccharide sequences and use thereof
PCT/FI2002/000674 WO2003016464A2 (en) 2001-08-17 2002-08-16 Cancer specific oligosaccharide sequences and use thereof
AU2002319338A AU2002319338A1 (en) 2001-08-17 2002-08-16 Cancer specific oligosaccharide sequences and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20011664A FI20011664A7 (fi) 2001-08-17 2001-08-17 Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö

Publications (3)

Publication Number Publication Date
FI20011664A0 FI20011664A0 (fi) 2001-08-17
FI20011664L true FI20011664L (fi) 2003-02-18
FI20011664A7 FI20011664A7 (fi) 2003-02-18

Family

ID=8561754

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20011664A FI20011664A7 (fi) 2001-08-17 2001-08-17 Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö

Country Status (6)

Country Link
US (1) US8313912B2 (fi)
EP (1) EP1417214A2 (fi)
JP (1) JP2005500057A (fi)
AU (1) AU2002319338A1 (fi)
FI (1) FI20011664A7 (fi)
WO (1) WO2003016464A2 (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011671L (fi) * 2001-08-20 2003-02-21 Carbion Oy Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
AU2002950878A0 (en) * 2002-08-20 2002-09-12 Proteome Systems Intellectual Property Pty Ltd Method for diagnosing disorders
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US7651847B2 (en) * 2004-06-22 2010-01-26 The Regents Of The University Of California Methods of oligosaccharide profiling for the detection of cancer
US7892752B2 (en) * 2005-04-26 2011-02-22 Dwek Raymond A Glycosylation markers for cancer diagnosing and monitoring
JP2008539412A (ja) * 2005-04-26 2008-11-13 レイモンド， エー． ドウェック， 癌の診断及びモニタリングのためのグリコシル化マーカー
US8039208B2 (en) * 2005-04-26 2011-10-18 National Institute For Bioprocessing Research And Training Limited (Nibrt) Automated strategy for identifying physiological glycosylation markers(s)
JP2008539413A (ja) * 2005-04-26 2008-11-13 レイモンド， エー． ドウェック， 自動化糖鎖フィンガープリント戦略
US20060269979A1 (en) * 2005-04-26 2006-11-30 Dwek Raymond A High throughput glycan analysis for diagnosing and monitoring rheumatoid arthritis and other autoimmune diseases
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
WO2007006870A2 (en) 2005-07-11 2007-01-18 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
FI20055417A0 (fi) * 2005-07-20 2005-07-20 Glykos Finland Oy Syöpäpesifiset glykaanit ja niiden käyttö
US7981625B2 (en) 2008-04-15 2011-07-19 The Board Of Trustees Of The Leland Stanford Junior University Prostate cancer glycan markers and autoantibody signatures
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
WO2010064683A1 (ja) 2008-12-03 2010-06-10 財団法人野口研究所 前立腺癌の判定方法
JP5443156B2 (ja) * 2009-12-28 2014-03-19 公益財団法人野口研究所 前立腺癌を判定する方法
GB201705686D0 (en) 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
EP3819639B1 (en) * 2018-07-11 2023-11-08 Japanese Foundation For Cancer Research Sugar chain specific to prostate cancer, and test method using same
CA3117208A1 (en) * 2018-11-08 2020-05-14 Dsm Ip Assets, B.V. Methods of selectively modulating gastrointestinal microbial growth
CN113645850A (zh) * 2018-11-08 2021-11-12 帝斯曼知识产权资产管理有限公司 调节胃肠代谢物的方法
CN112129938B (zh) * 2019-06-25 2023-08-18 中国科学院分子细胞科学卓越创新中心 UDP-Glc在肺癌转移评估中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH653442A5 (en) * 1982-01-29 1985-12-31 Otsuka Pharma Co Ltd Process for the determination of tumour-associated glucoside derivatives
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
US5660834A (en) * 1988-03-11 1997-08-26 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates
WO1993017033A1 (en) 1992-02-19 1993-09-02 The Biomembrane Institute Inhibition of cell adhesion by chemically-defined oligosaccharides, their derivatives, mimetics, and antibodies directed thereto
CZ39093A3 (en) 1992-03-12 1994-03-16 Lilly Co Eli Oligosaccharide and pharmaceutical preparation in which it is comprised
DE69738731D1 (de) * 1996-01-30 2008-07-10 Glycomimetics Inc SIALYL-LEWISa UND SIALYL-LEWISx EPITOPE ANALOGE
US5972907A (en) 1997-10-31 1999-10-26 Health Research, Inc. Synthetic core 2-like branched structures containing GalNAc-lewisx and Neu5Acα2-3Galβ1-3GalNAc sequences as novel ligands for selectins
US6261788B1 (en) * 1998-09-21 2001-07-17 The Board Of Regents Of The University Of Oklahoma Diagnostic assays for infectious parasitic helminths
JPWO2002077649A1 (ja) 2001-03-27 2004-07-15 帝国臓器製薬株式会社 乳癌診断法
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
EP1417214A2 (en) 2004-05-12
FI20011664A0 (fi) 2001-08-17
WO2003016464A3 (en) 2003-05-22
WO2003016464A2 (en) 2003-02-27
US8313912B2 (en) 2012-11-20
US20040253651A1 (en) 2004-12-16
JP2005500057A (ja) 2005-01-06
AU2002319338A1 (en) 2003-03-03
FI20011664A7 (fi) 2003-02-18

Similar Documents

Publication Publication Date Title
FI20011664L (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
FI20011671A0 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
DK3266791T3 (da) Mærkede nukleotider
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EP1379042A4 (en) MULTIPLEXER
DE50106015D1 (de) Osteosynthesemittel
DE60223576D1 (de) Hautbehandlungszusammensetzung
DE60225985D1 (de) Dentaleinheit
DE50209245D1 (de) Neuroprotektives medikament
DE60114244D1 (de) Osteosynthesevorrichtung
DE60220799D1 (de) Hypoglykämisches mittel
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
DE60136966D1 (de) Pflanzenstärkendes mittel
DE60219418T8 (de) Silanylphenole und -naphthole
DE50110467D1 (de) Staffelei
FI20012608A0 (fi) Diagnostiset menetelmät
DK1427748T3 (da) 17alfa-hydroxy-14beta-steroider med hormonal virkning
DE60204435D1 (de) Spritze
DE60206034D1 (de) Spritze
SE0100590D0 (sv) New composition and use
SE0104404D0 (sv) New methods and use

Legal Events

Date Code Title Description
MA Patent expired